The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Crescent Biopharma Inc | COM | G2545C104 | 5,270,638 | 361,250 | SH | SOLE | 0 | 361,250 | 0 | 0 | |
| Damora Therapeutics Inc | COM | G2646Y104 | 43,527,665 | 2,045,473 | SH | SOLE | 0 | 2,045,473 | 0 | 0 | |
| Jade Biosciences Inc | COM | 008064206 | 25,399,787 | 1,807,814 | SH | SOLE | 0 | 1,807,814 | 0 | 0 | |
| Korsana Biosciences Inc | COM | 23255M303 | 16,592,000 | 518,500 | SH | SOLE | 0 | 518,500 | 0 | 0 | |
| Oruka Therapeutics Inc | COM | 687604108 | 79,471,154 | 954,150 | SH | SOLE | 0 | 954,150 | 0 | 0 | |
| Spyre Therapeutics Inc | COM | 00773J202 | 103,329,999 | 1,160,620 | SH | SOLE | 0 | 1,160,620 | 0 | 0 | |